Tiansheng Pharmaceutical Group Co., Ltd. (SHE:002872)
5.08
+0.01 (0.20%)
Oct 27, 2025, 2:45 PM CST
SHE:002872 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Operating Revenue | 479.69 | 528.9 | 540.56 | 577.23 | 712.93 | 1,180 | Upgrade |
Other Revenue | 40.79 | 40.81 | 38.78 | 29.76 | 23.75 | 22.97 | Upgrade |
| 520.48 | 569.71 | 579.33 | 606.99 | 736.69 | 1,203 | Upgrade | |
Revenue Growth (YoY) | -8.27% | -1.66% | -4.56% | -17.61% | -38.75% | -28.39% | Upgrade |
Cost of Revenue | 271.7 | 308.57 | 322.36 | 279.1 | 441.56 | 873.3 | Upgrade |
Gross Profit | 248.78 | 261.14 | 256.97 | 327.89 | 295.12 | 329.44 | Upgrade |
Selling, General & Admin | 293.4 | 298.51 | 312.22 | 392 | 328.41 | 447.02 | Upgrade |
Research & Development | 19.9 | 22.75 | 30.92 | 34.27 | 29.24 | 22.46 | Upgrade |
Other Operating Expenses | -4.92 | 1.22 | -4.44 | -6 | -7.68 | -12.99 | Upgrade |
Operating Expenses | 314.11 | 321.7 | 342.93 | 421.54 | 367.56 | 452.04 | Upgrade |
Operating Income | -65.33 | -60.56 | -85.96 | -93.65 | -72.44 | -122.6 | Upgrade |
Interest Expense | -14.27 | -14.78 | -14.99 | -15.78 | -24.36 | -38.89 | Upgrade |
Interest & Investment Income | 23.72 | 24.1 | 10.08 | 12.63 | 21.8 | 5.92 | Upgrade |
Currency Exchange Gain (Loss) | - | - | - | - | - | -0.07 | Upgrade |
Other Non Operating Income (Expenses) | -12.54 | -22.7 | -4.67 | -9.5 | -1.83 | -3.05 | Upgrade |
EBT Excluding Unusual Items | -68.41 | -73.95 | -95.55 | -106.31 | -76.82 | -158.67 | Upgrade |
Impairment of Goodwill | - | - | - | - | -2.49 | -0.57 | Upgrade |
Gain (Loss) on Sale of Investments | 2.18 | 1.18 | 0.33 | -0.19 | -0.39 | -2.57 | Upgrade |
Gain (Loss) on Sale of Assets | -0.05 | 0.04 | 0.23 | 9.53 | 5.22 | 0.73 | Upgrade |
Asset Writedown | -24.15 | -24.18 | -4.81 | -3.21 | -5.99 | -367.36 | Upgrade |
Other Unusual Items | 1.03 | -0.89 | 5.07 | 16.07 | 26.03 | -6.13 | Upgrade |
Pretax Income | -89.41 | -97.79 | -94.72 | -84.12 | -54.44 | -534.58 | Upgrade |
Income Tax Expense | -7.9 | -9.64 | -1.01 | 7.44 | 17.89 | -40.99 | Upgrade |
Earnings From Continuing Operations | -81.5 | -88.15 | -93.71 | -91.55 | -72.34 | -493.59 | Upgrade |
Minority Interest in Earnings | 0.5 | 0.74 | 0.64 | 0.99 | 4.53 | 2.85 | Upgrade |
Net Income | -81.01 | -87.4 | -93.07 | -90.56 | -67.81 | -490.73 | Upgrade |
Net Income to Common | -81.01 | -87.4 | -93.07 | -90.56 | -67.81 | -490.73 | Upgrade |
Shares Outstanding (Basic) | 318 | 318 | 318 | 318 | 318 | 318 | Upgrade |
Shares Outstanding (Diluted) | 318 | 318 | 318 | 318 | 318 | 318 | Upgrade |
Shares Change (YoY) | 0.04% | -0.01% | -0.00% | -0.01% | 0.01% | -0.50% | Upgrade |
EPS (Basic) | -0.25 | -0.27 | -0.29 | -0.28 | -0.21 | -1.54 | Upgrade |
EPS (Diluted) | -0.25 | -0.27 | -0.29 | -0.28 | -0.21 | -1.54 | Upgrade |
Free Cash Flow | 43.38 | -0.13 | -101.3 | 15.76 | -95.41 | 97.05 | Upgrade |
Free Cash Flow Per Share | 0.14 | - | -0.32 | 0.05 | -0.30 | 0.30 | Upgrade |
Gross Margin | 47.80% | 45.84% | 44.36% | 54.02% | 40.06% | 27.39% | Upgrade |
Operating Margin | -12.55% | -10.63% | -14.84% | -15.43% | -9.83% | -10.19% | Upgrade |
Profit Margin | -15.56% | -15.34% | -16.07% | -14.92% | -9.20% | -40.80% | Upgrade |
Free Cash Flow Margin | 8.33% | -0.02% | -17.49% | 2.60% | -12.95% | 8.07% | Upgrade |
EBITDA | 40.55 | 45.11 | 18.21 | 11.85 | 14.92 | -5.54 | Upgrade |
EBITDA Margin | 7.79% | 7.92% | 3.14% | 1.95% | 2.02% | -0.46% | Upgrade |
D&A For EBITDA | 105.88 | 105.67 | 104.17 | 105.51 | 87.36 | 117.05 | Upgrade |
EBIT | -65.33 | -60.56 | -85.96 | -93.65 | -72.44 | -122.6 | Upgrade |
EBIT Margin | -12.55% | -10.63% | -14.84% | -15.43% | -9.83% | -10.19% | Upgrade |
Revenue as Reported | 520.48 | 569.71 | 579.33 | 606.99 | 736.69 | 1,203 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.